Trials / Conditions / Migraine With or Without Aura

Migraine With or Without Aura

21 registered clinical trials studyying Migraine With or Without Aura — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea NCT07497854	Pfizer	—
Completed	Evaluation of a Wearable Device for Acute Treatment of Migraines NCT07015125	Hinge Health, Inc	N/A
Completed	Cooling to Alleviate Migraine #3 NCT06874361	Mi-Helper, Inc.	N/A
Recruiting	New Methods for Evaluating Preventive Migraine Treatment NCT07071506	University of Aarhus	N/A
Active Not Recruiting	Exploring the Effect of the Transcendental Meditation® Technique on Migraine Frequency and Functionality: A Si NCT06695156	Maharishi International University	N/A
Completed	Trial in Adult Subjects With Acute Migraines NCT03461757	Pfizer	Phase 3
Completed	Open Label Safety Study in Acute Treatment of Migraine NCT03266588	Pfizer	Phase 2 / Phase 3
Completed	The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination NCT03194555	Allodynic Therapeutics, Inc	Phase 2
Completed	Safety and Efficacy in Adult Subjects With Acute Migraines NCT03237845	Pfizer	Phase 3
Completed	Safety and Efficacy Study in Adult Subjects With Acute Migraines NCT03235479	Pfizer	Phase 3
Completed	An Acute Migraine Factorial Study NCT06245902	Allodynic Therapeutics, Inc	Phase 2
Completed	Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine NCT03061734	Allodynic Therapeutics, Inc	Phase 2
Completed	An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migrain NCT02873221	Allergan	Phase 3
Completed	Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migr NCT02848326	Allergan	Phase 2 / Phase 3
Completed	Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine NCT02867709	Allergan	Phase 3
Completed	Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine NCT02828020	Allergan	Phase 3
Completed	Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine NCT02605174	Eli Lilly and Company	Phase 3
Completed	Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatrip NCT01989936	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Phase 3
Completed	Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo NCT01986270	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Phase 3
Completed	Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study NCT01986088	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Phase 3
Completed	Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine NCT01978496	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Phase 3